Aliskiren and losartan trial in non-diabetic chronic kidney disease

Area of Science:

• Nephrology
• Pharmacology
• Clinical Trials

Background:

• Investigating therapeutic strategies for non-diabetic chronic kidney disease (CKD).
• Evaluating the efficacy and safety of aliskiren and angiotensin II receptor blockers (ARBs) in CKD management.
• Assessing combination therapy versus monotherapy over a 3-year period.

Purpose of the Study:

• To compare the therapeutic efficacy and safety of combined aliskiren and ARB therapy versus aliskiren alone and ARB alone in non-diabetic CKD patients.
• To determine if combination therapy offers superior renal protection or improved proteinuria reduction compared to monotherapy.
• To evaluate the long-term outcomes of different treatment regimens in managing non-diabetic CKD.

Main Methods:

• A randomized clinical trial involving 155 non-diabetic CKD patients.
• Three treatment groups: aliskiren alone (150 mg/day), losartan (ARB) alone (100 mg/day), and combination therapy (aliskiren 150 mg/day + losartan 100 mg/day).
• Primary renal endpoints included estimated glomerular filtration rate (eGFR) <15 ml/min or end-stage renal failure.

Main Results:

• All treatment groups demonstrated a significant reduction in proteinuria (p<0.001).
• No significant differences were observed in the changes of eGFR or total urinary protein from baseline across the three groups over the study period.
• One non-fatal stroke occurred in the combination therapy group; no strokes were reported in the monotherapy groups.

Conclusions:

• Combination therapy with aliskiren and ARB is as efficacious as monotherapy with either agent in non-diabetic CKD patients.
• The study suggests comparable long-term renal outcomes and proteinuria reduction between combination and monotherapy.
• While generally safe, the potential for adverse events like stroke in combination therapy warrants consideration.